Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis

European Journal of Inflammation

Volumn 9, Issue 3, 2011, Pages 289-292

  Kourelis, Taxiarchis V ^a   Moustakakis, M N ^b   Silk, R ^c   Pharm, D ^b   Boruchov, A ^b   Bilgrami, S F ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^c NONE

Author keywords

Acute myeloid leukemia; Decitabine; Hemodialysis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; IDARUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DRUG WITHDRAWAL; GRAFT REJECTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MALE; MEDICAL HISTORY; PANCYTOPENIA; TREATMENT OUTCOME;

EID: 84858629916     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900310     Document Type: Article

References (13)

1. Sauer H, Fuger K, Blumenstein M. Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo. Cancer Treat Rev 1990; 17:293-300.
2. Regardh CG. Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion. J Clin Hosp Pharm 1985; 10:337-49. (Pubitemid 16206313)
3. Smith GA, Damon DL, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 5:833-39. (Pubitemid 27075136)
4. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009; 115:5746.
5. Kantarjian HM, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-803.
6. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27:3842-48.
7. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983; 43:592-97. (Pubitemid 13193853)
8. Momparler RL. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 1985; 30:287-99. (Pubitemid 17207210)
9. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 2005; 42:S9-16.
10. Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndrome. Onco Targets Ther 2010; 10:1-13.
11. Van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986; 46:4831-36. (Pubitemid 16000370)
12. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharnacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008; 61:759-66. (Pubitemid 351302031)
13. Batty GN, Kantarjian H, Issa J-P, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 2010; 10:205-10.